Table 3.
Fibrosis Stage | ≥I1 | ≥I2 | ≥I3 | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Study | Manufacturer | Cut-Off (m/s/kHz) |
AUROC | Se/Sp (%) |
Cut-Off (m/s/kHz) |
AUROC | Se/Sp (%) |
Cut-Off (m/s/kHz) |
AUROC | Se/Sp (%) |
Sugimoto [86], 2020 (n = 111) |
Canon Medical Systems | 8.5 | 0.95 | 94/100 | 9.9 | 0.81 | 89/66 | 12.5 | 0.85 | 83 |
Lee [85], 2021 (n = 102) |
Canon Medical Systems | 10.5 | 0.89 | 74/96 | 10.5 | 0.85 | 85/74 | 11.7 | 0.78 | 100/63 |
9.1 | 0.89 | 91/58 | 9.9 | 0.85 | 92/62 | 11.7 | 0.78 | 100/63 | ||
10.4 | 0.89 | 75/92 | 12.8 | 0.85 | 50/90 | 19.7 | 0.78 | 0/100 | ||
Jang [87], 2022 (n = 132) |
Canon Medical Systems | 10.8 | 0.86 | 82/82 | 82/82 | 0.86 | 90/77 | 11.6 | 0.79 | 100/61 |
AUROC—area under the ROC curve; Se—sensitivity; Sp—specificity; N/S—not specified; n—population; I1—mild lobular inflammation grade; I2—moderate lobular inflammation grade; I3—severe lobular inflammation grade. In conclusion, due to the recent advancements of 2D-SWE techniques and promising future developments, we can obtain, in a non-invasive manner, valuable information regarding fibrosis, steatosis, and possible inflammation in both chronic and acute liver diseases [104,105].